Combination therapy may create a practice change for advanced or recurrent endometrial cancer

This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, two new studies show the value of adding immunotherapy to standard‐of‐care chemotherapy to improve progression‐free survival in endometrial cancer. In addition, mirvetuximab soravtansine is confirmed as a new standard of care for platinum‐resistant ovarian cancer, and leaving ovaries during benign hysterectomies may have benefits that outweigh the potential risks of removing them.